Clinical Trials
The Department of Psychiatry conducts clinical trials to explore new treatments for various disorders, including depression, bipolar disorder and schizophrenia.
Assessments and treatments are provided at no cost. Participants are compensated for their time.
For more information call 614-293-7109 or email: Clinicaltrials@osumc.edu.
Currently enrolling studies
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder
Description of Study: A 6-week study to evaluate the efficacy of ABBV-932 compared to placebo on symptoms of depression in participants with bipolar disorder.
Eligibility Criteria:
- Adults 18-64
- Diagnosed with Bipolar Disorder I or II
- Currently in a depressive episode
- Not currently receiving treatment
- Otherwise medically stable
Principal Investigator: Subhdeep Virk, MD
Contact: Phone: 614-293-7109
Email: Clinicaltrials@osumc.edu
Funding/Study Sponsor: Abbvie Inc
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)
Description of Study: A study to evaluate the efficacy of Vagus Nerve Stimulation (VNS) on symptoms of depression in participants with bipolar disorder in a major depressive episode.
Eligibility Criteria:
- Adults 18 and older
- Diagnosed with Bipolar Disorder I or II
- Currently in a depressive episode
- Failed four prior antidepressant treatments
Principal Investigator: Kevin Reeves, MD
Contact: Phone: 614-293-7109
Email: Clinicaltrials@osumc.edu
Funding/Study Sponsor: LivaNova
Source: https://classic.clinicaltrials.gov/ct2/show/NCT03887715
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open label Long-term Extension Treatment with Aticaprant
Description of Study: A 6-week study to find out whether a medicine called Aticaprant helps to improve symptoms of depression. Participants continue their standard antidepressant therapy throughout the study.
Eligibility Criteria:
- Adults 18–65
- Diagnosed with MDD
- Inadequate response to current antidepressant therapy
- Otherwise medically stable
Principal Investigator: Subhdeep Virk, MD
Contact: Phone: 614-293-7109
Email: Clinicaltrials@osumc.edu
Funding/Study Sponsor: Janssen Research & Development, LLC
Source: https://globaltrialfinder.janssen.com/trial/67953964mdd3007
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults with Major Depressive Disorder
Description of Study: A 14-week study to evaluate the efficacy of SEP-363856 compared to placebo used in addition to oral antidepressants in adults with MDD
Eligibility Criteria:
- Adults 18-65
- Diagnosed with MDD
- Current major depressive episode must be at least 8 weeks
- Inadequate response to current antidepressant therapy
- Otherwise medically stable
Principal Investigator: Subhdeep Virk, MD
Contact: Phone: 614-293-7109
Email: Clinicaltrials@osumc.edu
Funding/Study Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Source: https://classic.clinicaltrials.gov/ct2/show/NCT05593029
Efficacy, Safety, and Tolerability of Administrations of COMP360 in Participants with TRD (treatment-resistant depression)
Description of Study: A 52-week study to assess the efficacy of COMP360 (psilocybin), administered with psychological support in adult participants with TRD (treatment resistant depression), in improving symptoms of depression.
Eligibility Criteria:
- Adults 18 and older
- Diagnosed with TRD
- Currently in a major depressive episode
- Otherwise medically stable
Principal Investigator: Subhdeep Virk, MD
Contact: Phone: 614-293-7109
Email: Clinicaltrials@osumc.edu
Funding/Study Sponsor: COMPASS Pathways
Source: https://classic.clinicaltrials.gov/ct2/show/NCT05624268
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Description of Study: A 6-week study to evaluate the efficacy of Lumateperone compared to placebo used in addition to oral antidepressants in adults with MDD.
Eligibility Criteria:
- Adults 18-65
- Diagnosed with MDD
- Current major depressive episode
- Inadequate response to current antidepressant therapy
- Otherwise medically stable
Principal Investigator: Subhdeep Virk, MD
Contact: Phone: 614-293-7109
Email: Clinicaltrials@osumc.edu
Funding/Study Sponsor: Intra-Cellular Therapies, Inc.
Source: https://classic.clinicaltrials.gov/ct2/show/NCT05850689
A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients with Postpartum Depression (PPD)
Description of Study: A 4-week study to evaluate the efficacy of RE104 in adults with PPD.
Eligibility Criteria:
- Adults 18-45
- Diagnosed with PPD
- Currently in a major depressive episode
- No longer breastfeeding
- Otherwise medically stable
Principal Investigator: Subhdeep Virk, MD
Contact: Phone: 614-293-7109
Email: Clinicaltrials@osumc.edu
Funding/Study Sponsor: Reunion Neuroscience
Source: https://ctv.veeva.com/study/re104-safety-and-efficacy-study-in-postpartum-depression